Treatment Outcomes of Esophageal Cancer

University of California San Francisco (UCSF)

Status

Enrolling

Conditions

Esophageal Cancer

Treatments

Other: Assessment of patient-reported outcomes (PROs)

Study type

Observational

Funder types

Other

Industry

NIH

Identifiers

NCT05177393

204510 (Other Identifier)

TOEC-AfrECC

3P30CA082103-21SA (U.S. NIH Grant/Contract)

21455

184510 (Other Identifier)

184515 (Other Identifier)

214520 (Other Identifier)

Details and patient eligibility

About

This study will be a carried out through a prospective observational cohort design in conjunction with researchers in the African Esophageal Cancer Consortium (AfrECC). The purpose of this research is to prospectively evaluate outcomes related to existing treatment strategies for esophageal cancer (EC) at participating sites within AfrECC.

Full description

SPECIFIC AIMS:

Aim 1: To describe the types of treatments administered for all patients diagnosed with EC at participating AfrECC sites, including chemotherapeutic regimens, radiation therapy, chemo-radiotherapy, esophageal stenting, esophagectomy, and basic supportive care.

Aim 2: To evaluate the effect of different EC treatment modalities on patient reported outcomes during and after completion of treatment.

Aim 3: To measure the effect of different treatment modalities on overall survival.

Enrollment

2,476 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Participants with histopathologically confirmed or presumptive clinical diagnosis of EC. For patients who do not have histopathologically confirmed disease, presumptive clinical diagnosis may be based upon barium swallow or endoscopy without biopsy.
Age 18 years of age or older;

Exclusion criteria